Viking Therapeutics Accelerates Obesity Drug Trial Enrollment
20.11.2025 - 08:58:04 | boerse-global.de
Viking Therapeutics has achieved a significant advancement in its obesity treatment program, completing patient enrollment for its pivotal Phase 3 clinical trial ahead of schedule. This development positions the biotechnology firm more competitively in the lucrative weight-loss medication sector, where multiple pharmaceutical companies are vying for market share.
The VANQUISH-1 study has successfully enrolled approximately 4,650 adult participants living with overweight or obesity conditions, surpassing initial recruitment targets. This randomized, double-blind, placebo-controlled investigation will evaluate both the safety profile and therapeutic effectiveness of VK2735 across a 78-week treatment period.
The primary objective established for this clinical research is measuring the percentage reduction in body weight compared to placebo following the completion Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.
